H.C. Wainwright analyst Matthew Caufield downgraded Adverum Biotechnologies (ADVM) to Neutral from Buy with a price target of $5, down from $30, after the company entered into an agreement to be acquired by Eli Lilly (LLY).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADVM:
- Adverum Biotechnologies price target lowered to $5.50 from $12 at Mizuho
- Adverum Biotechnologies price target raised to $4 from $3 at RBC Capital
- Adverum Biotechnologies’ Phase 3 Study on Ixo-vec: A Potential Game-Changer for AMD Treatment
- Adverum Biotechnologies downgraded to Neutral from Buy at Chardan
- M&A News: Eli Lilly’s (LLY) $262M Acquisition of Adverum Bolsters Gene Therapy Push